Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | ATP4A | P20648 | 2/20 | 0.40 |
| ▸ | ATP4B | P51164 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | CYP24A1 | Q07973 | 2/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | DHFR | P00374 | 1/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4155688 | 1.00 | NFE2L2 (0.42) | NFE2L2TRPA1MAPK1ATP4AATP4B | |
| SCHEMBL4163353 | 0.83 | MAPK1 (0.47) | NFE2L2TRPA1MAPK1ATP4AATP4B | |
| SCHEMBL4163348 | 0.83 | MAPK1 (0.47) | NFE2L2TRPA1MAPK1ATP4AATP4B | |
| SCHEMBL285349 | 0.72 | NR1H2 (0.42) | NFE2L2TRPA1ATP4AATP4BKDM4E | |
| SCHEMBL7098110 | 0.71 | NFE2L2 (0.37) | NFE2L2TRPA1ATP4AATP4BKDM4E | |
| SCHEMBL10653293 | 0.71 | KDM4E (0.72) | MAPK1KDM4EALDH1A1NPC1MEN1 | |
| SCHEMBL11410050 | 0.71 | KDM4E (0.72) | MAPK1KDM4EALDH1A1NPC1MEN1 | |
| SCHEMBL44502 | 0.69 | NFE2L2 (0.68) | NFE2L2TRPA1CYP11B1CYP11B2MEN1 | |
| SCHEMBL44503 | 0.69 | NFE2L2 (0.68) | NFE2L2TRPA1CYP11B1CYP11B2MEN1 | |
| SCHEMBL6360540 | 0.69 | NFE2L2 (0.68) | NFE2L2TRPA1CYP11B1CYP11B2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8212048-B2 | Method of producing aromatic compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20090043096-A1 | METHOD OF PRODUCING AROMATIC COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090043096-A1 | METHOD OF PRODUCING AROMATIC COMPOUND | AHR, CYP1A1, ARNT | NFE2L2 15/4885TRPA1 267/4885MAPK1 1786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.